Discrimination and Calibration of the Veterans Aging Cohort Study Index 2.0 for Predicting Mortality Among People With Human Immunodeficiency Virus in North America

Discrimination and Calibration of the Veterans Aging Cohort Study Index 2.0 for Predicting Mortality Among People With Human Immunodeficiency Virus in North America. McGinnis, K. A, Justice, A. C, Moore, R. D, Silverberg, M. J, Althoff, K. N, Karris, M., Lima, V. D, Crane, H. M, Horberg, M. A, Klein, M. B, Gange, S. J, Gebo, K. A, Mayor, A., Tate, J. P, North American AIDS Cohort Collaboration on Research, of the International Epidemiologic Databases to Evaluate AIDS (IeDEA), D. (., & (VACS), V. A. C. S. Clinical Infectious Diseases, October, 2021.

Paper doi abstract bibtex

The updated Veterans Aging Cohort Study (VACS) Index 2.0 combines general and human immunodeficiency virus (HIV)–specific biomarkers to generate a continuous score that accurately discriminates risk of mortality in diverse cohorts of persons with HIV (PWH), but a score alone is difficult to interpret. Using data from the North American AIDS Cohort Collaboration (NA-ACCORD), we translate VACS Index 2.0 scores into validated probability estimates of mortality.Because complete mortality ascertainment is essential for accurate calibration, we restricted analyses to cohorts with mortality from the National Death Index or equivalent sources. VACS Index 2.0 components were ascertained from October 1999 to April 2018. Mortality was observed up to March 2019. Calibration curves compared predicted (estimated by fitting a gamma model to the score) to observed mortality overall and within subgroups: cohort (VACS/NA-ACCORD subset), sex, age <50 or ≥50 years, race/ethnicity, HIV-1 RNA ≤500 or >500 copies/mL, CD4 count <350 or ≥350 cells/µL, and years 1999–2009 or 2010–2018. Because mortality rates have decreased over time, the final model was limited to 2010–2018.Among 37230 PWH in VACS and 8061 PWH in the NA-ACCORD subset, median age was 53 and 44 years; 3% and 19% were women; and 48% and 39% were black. Discrimination in NA-ACCORD (C-statistic = 0.842 [95% confidence interval \CI\, .830–.854]) was better than in VACS (C-statistic = 0.813 [95% CI, .809–.817]). Predicted and observed mortality largely overlapped in VACS and the NA-ACCORD subset, overall and within subgroups.Based on this validation, VACS Index 2.0 can reliably estimate probability of all-cause mortality, at various follow-up times, among PWH in North America.

@article{mcginnis_discrimination_2021,
	title = {Discrimination and {Calibration} of the {Veterans} {Aging} {Cohort} {Study} {Index} 2.0 for {Predicting} {Mortality} {Among} {People} {With} {Human} {Immunodeficiency} {Virus} in {North} {America}},
	issn = {1058-4838},
	url = {https://doi.org/10.1093/cid/ciab883},
	doi = {10.1093/cid/ciab883},
	abstract = {The updated Veterans Aging Cohort Study (VACS) Index 2.0 combines general and human immunodeficiency virus (HIV)–specific biomarkers to generate a continuous score that accurately discriminates risk of mortality in diverse cohorts of persons with HIV (PWH), but a score alone is difficult to interpret. Using data from the North American AIDS Cohort Collaboration (NA-ACCORD), we translate VACS Index 2.0 scores into validated probability estimates of mortality.Because complete mortality ascertainment is essential for accurate calibration, we restricted analyses to cohorts with mortality from the National Death Index or equivalent sources. VACS Index 2.0 components were ascertained from October 1999 to April 2018. Mortality was observed up to March 2019. Calibration curves compared predicted (estimated by fitting a gamma model to the score) to observed mortality overall and within subgroups: cohort (VACS/NA-ACCORD subset), sex, age \&lt;50 or ≥50 years, race/ethnicity, HIV-1 RNA ≤500 or \&gt;500 copies/mL, CD4 count \&lt;350 or ≥350 cells/µL, and years 1999–2009 or 2010–2018. Because mortality rates have decreased over time, the final model was limited to 2010–2018.Among 37230 PWH in VACS and 8061 PWH in the NA-ACCORD subset, median age was 53 and 44 years; 3\% and 19\% were women; and 48\% and 39\% were black. Discrimination in NA-ACCORD (C-statistic = 0.842 [95\% confidence interval \{CI\}, .830–.854]) was better than in VACS (C-statistic = 0.813 [95\% CI, .809–.817]). Predicted and observed mortality largely overlapped in VACS and the NA-ACCORD subset, overall and within subgroups.Based on this validation, VACS Index 2.0 can reliably estimate probability of all-cause mortality, at various follow-up times, among PWH in North America.},
	urldate = {2022-01-24},
	journal = {Clinical Infectious Diseases},
	author = {McGinnis, Kathleen A and Justice, Amy C and Moore, Richard D and Silverberg, Michael J and Althoff, Keri N and Karris, Maile and Lima, Viviane D and Crane, Heidi M and Horberg, Michael A and Klein, Marina B and Gange, Stephen J and Gebo, Kelly A and Mayor, Angel and Tate, Janet P and {North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)a of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) and Veterans Aging Cohort Study (VACS)}},
	month = oct,
	year = {2021},
	pages = {ciab883},
}

Downloads: 0

{"_id":"9HTKYJT2rbfPKoNpT","bibbaseid":"mcginnis-justice-moore-silverberg-althoff-karris-lima-crane-etal-discriminationandcalibrationoftheveteransagingcohortstudyindex20forpredictingmortalityamongpeoplewithhumanimmunodeficiencyvirusinnorthamerica-2021","author_short":["McGinnis, K. A","Justice, A. C","Moore, R. D","Silverberg, M. J","Althoff, K. N","Karris, M.","Lima, V. D","Crane, H. M","Horberg, M. A","Klein, M. B","Gange, S. J","Gebo, K. A","Mayor, A.","Tate, J. P","North American AIDS Cohort Collaboration on Research","of the International Epidemiologic Databases to Evaluate AIDS (IeDEA), D. (.","(VACS), V. A. C. S."],"bibdata":{"bibtype":"article","type":"article","title":"Discrimination and Calibration of the Veterans Aging Cohort Study Index 2.0 for Predicting Mortality Among People With Human Immunodeficiency Virus in North America","issn":"1058-4838","url":"https://doi.org/10.1093/cid/ciab883","doi":"10.1093/cid/ciab883","abstract":"The updated Veterans Aging Cohort Study (VACS) Index 2.0 combines general and human immunodeficiency virus (HIV)–specific biomarkers to generate a continuous score that accurately discriminates risk of mortality in diverse cohorts of persons with HIV (PWH), but a score alone is difficult to interpret. Using data from the North American AIDS Cohort Collaboration (NA-ACCORD), we translate VACS Index 2.0 scores into validated probability estimates of mortality.Because complete mortality ascertainment is essential for accurate calibration, we restricted analyses to cohorts with mortality from the National Death Index or equivalent sources. VACS Index 2.0 components were ascertained from October 1999 to April 2018. Mortality was observed up to March 2019. Calibration curves compared predicted (estimated by fitting a gamma model to the score) to observed mortality overall and within subgroups: cohort (VACS/NA-ACCORD subset), sex, age <50 or ≥50 years, race/ethnicity, HIV-1 RNA ≤500 or >500 copies/mL, CD4 count <350 or ≥350 cells/µL, and years 1999–2009 or 2010–2018. Because mortality rates have decreased over time, the final model was limited to 2010–2018.Among 37230 PWH in VACS and 8061 PWH in the NA-ACCORD subset, median age was 53 and 44 years; 3% and 19% were women; and 48% and 39% were black. Discrimination in NA-ACCORD (C-statistic = 0.842 [95% confidence interval \\CI\\, .830–.854]) was better than in VACS (C-statistic = 0.813 [95% CI, .809–.817]). Predicted and observed mortality largely overlapped in VACS and the NA-ACCORD subset, overall and within subgroups.Based on this validation, VACS Index 2.0 can reliably estimate probability of all-cause mortality, at various follow-up times, among PWH in North America.","urldate":"2022-01-24","journal":"Clinical Infectious Diseases","author":[{"propositions":[],"lastnames":["McGinnis"],"firstnames":["Kathleen","A"],"suffixes":[]},{"propositions":[],"lastnames":["Justice"],"firstnames":["Amy","C"],"suffixes":[]},{"propositions":[],"lastnames":["Moore"],"firstnames":["Richard","D"],"suffixes":[]},{"propositions":[],"lastnames":["Silverberg"],"firstnames":["Michael","J"],"suffixes":[]},{"propositions":[],"lastnames":["Althoff"],"firstnames":["Keri","N"],"suffixes":[]},{"propositions":[],"lastnames":["Karris"],"firstnames":["Maile"],"suffixes":[]},{"propositions":[],"lastnames":["Lima"],"firstnames":["Viviane","D"],"suffixes":[]},{"propositions":[],"lastnames":["Crane"],"firstnames":["Heidi","M"],"suffixes":[]},{"propositions":[],"lastnames":["Horberg"],"firstnames":["Michael","A"],"suffixes":[]},{"propositions":[],"lastnames":["Klein"],"firstnames":["Marina","B"],"suffixes":[]},{"propositions":[],"lastnames":["Gange"],"firstnames":["Stephen","J"],"suffixes":[]},{"propositions":[],"lastnames":["Gebo"],"firstnames":["Kelly","A"],"suffixes":[]},{"propositions":[],"lastnames":["Mayor"],"firstnames":["Angel"],"suffixes":[]},{"propositions":[],"lastnames":["Tate"],"firstnames":["Janet","P"],"suffixes":[]},{"firstnames":[],"propositions":[],"lastnames":["North American AIDS Cohort Collaboration on Research"],"suffixes":[]},{"firstnames":["Design","(NA-ACCORD)a"],"propositions":["of","the","International","Epidemiologic","Databases","to"],"lastnames":["Evaluate","AIDS","(IeDEA)"],"suffixes":[]},{"firstnames":["Veterans","Aging","Cohort","Study"],"propositions":[],"lastnames":["(VACS)"],"suffixes":[]}],"month":"October","year":"2021","pages":"ciab883","bibtex":"@article{mcginnis_discrimination_2021,\n\ttitle = {Discrimination and {Calibration} of the {Veterans} {Aging} {Cohort} {Study} {Index} 2.0 for {Predicting} {Mortality} {Among} {People} {With} {Human} {Immunodeficiency} {Virus} in {North} {America}},\n\tissn = {1058-4838},\n\turl = {https://doi.org/10.1093/cid/ciab883},\n\tdoi = {10.1093/cid/ciab883},\n\tabstract = {The updated Veterans Aging Cohort Study (VACS) Index 2.0 combines general and human immunodeficiency virus (HIV)–specific biomarkers to generate a continuous score that accurately discriminates risk of mortality in diverse cohorts of persons with HIV (PWH), but a score alone is difficult to interpret. Using data from the North American AIDS Cohort Collaboration (NA-ACCORD), we translate VACS Index 2.0 scores into validated probability estimates of mortality.Because complete mortality ascertainment is essential for accurate calibration, we restricted analyses to cohorts with mortality from the National Death Index or equivalent sources. VACS Index 2.0 components were ascertained from October 1999 to April 2018. Mortality was observed up to March 2019. Calibration curves compared predicted (estimated by fitting a gamma model to the score) to observed mortality overall and within subgroups: cohort (VACS/NA-ACCORD subset), sex, age \\<50 or ≥50 years, race/ethnicity, HIV-1 RNA ≤500 or \\>500 copies/mL, CD4 count \\<350 or ≥350 cells/µL, and years 1999–2009 or 2010–2018. Because mortality rates have decreased over time, the final model was limited to 2010–2018.Among 37230 PWH in VACS and 8061 PWH in the NA-ACCORD subset, median age was 53 and 44 years; 3\\% and 19\\% were women; and 48\\% and 39\\% were black. Discrimination in NA-ACCORD (C-statistic = 0.842 [95\\% confidence interval \\{CI\\}, .830–.854]) was better than in VACS (C-statistic = 0.813 [95\\% CI, .809–.817]). Predicted and observed mortality largely overlapped in VACS and the NA-ACCORD subset, overall and within subgroups.Based on this validation, VACS Index 2.0 can reliably estimate probability of all-cause mortality, at various follow-up times, among PWH in North America.},\n\turldate = {2022-01-24},\n\tjournal = {Clinical Infectious Diseases},\n\tauthor = {McGinnis, Kathleen A and Justice, Amy C and Moore, Richard D and Silverberg, Michael J and Althoff, Keri N and Karris, Maile and Lima, Viviane D and Crane, Heidi M and Horberg, Michael A and Klein, Marina B and Gange, Stephen J and Gebo, Kelly A and Mayor, Angel and Tate, Janet P and {North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD)a of the International Epidemiologic Databases to Evaluate AIDS (IeDEA) and Veterans Aging Cohort Study (VACS)}},\n\tmonth = oct,\n\tyear = {2021},\n\tpages = {ciab883},\n}\n\n\n\n\n\n\n\n","author_short":["McGinnis, K. A","Justice, A. C","Moore, R. D","Silverberg, M. J","Althoff, K. N","Karris, M.","Lima, V. D","Crane, H. M","Horberg, M. A","Klein, M. B","Gange, S. J","Gebo, K. A","Mayor, A.","Tate, J. P","North American AIDS Cohort Collaboration on Research","of the International Epidemiologic Databases to Evaluate AIDS (IeDEA), D. (.","(VACS), V. A. C. S."],"key":"mcginnis_discrimination_2021","id":"mcginnis_discrimination_2021","bibbaseid":"mcginnis-justice-moore-silverberg-althoff-karris-lima-crane-etal-discriminationandcalibrationoftheveteransagingcohortstudyindex20forpredictingmortalityamongpeoplewithhumanimmunodeficiencyvirusinnorthamerica-2021","role":"author","urls":{"Paper":"https://doi.org/10.1093/cid/ciab883"},"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"http://bibbase.org/zotero-group/lober/2427847","dataSources":["K7F7TwXAn7H3rFsQm","ubcxGhA3gPABESuE5"],"keywords":[],"search_terms":["discrimination","calibration","veterans","aging","cohort","study","index","predicting","mortality","people","human","immunodeficiency","virus","north","america","mcginnis","justice","moore","silverberg","althoff","karris","lima","crane","horberg","klein","gange","gebo","mayor","tate","north american aids cohort collaboration on research","of the international epidemiologic databases to evaluate aids (iedea)","(vacs)"],"title":"Discrimination and Calibration of the Veterans Aging Cohort Study Index 2.0 for Predicting Mortality Among People With Human Immunodeficiency Virus in North America","year":2021}